AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Vistagen Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S67BH3
0.18▼ 0.01 (-3.90%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
0.19
Day's Range
0.18 – 0.19
52-Week Range
0.18 – 5.14
Volume
1.2M
Avg Volume
21.0M
Share Statistics
Shares Outstanding
Employees
59
Exchange
XNAS
Listed
2009-07-01
Share count as of August 10, 2026

Vistagen Therapeutics, Inc. Common Stock (VTGN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Vistagen Therapeutics, Inc. Common Stock (VTGN)
What is Vistagen Therapeutics, Inc. Common Stock's Market Cap?
Vistagen Therapeutics, Inc. Common Stock's Market Cap is $8.0M, based on as-reported figures from SEC (XBRL) filings.
What is Vistagen Therapeutics, Inc. Common Stock's Price / Sales?
Vistagen Therapeutics, Inc. Common Stock's Price / Sales is 3.2×, based on as-reported figures from SEC (XBRL) filings.
What is Vistagen Therapeutics, Inc. Common Stock's Revenue (TTM)?
Vistagen Therapeutics, Inc. Common Stock's Revenue (TTM) is $2.5M, based on as-reported figures from SEC (XBRL) filings.
What is Vistagen Therapeutics, Inc. Common Stock's Net Income (TTM)?
Vistagen Therapeutics, Inc. Common Stock's Net Income (TTM) is -$67.6M, based on as-reported figures from SEC (XBRL) filings.
What is Vistagen Therapeutics, Inc. Common Stock's EBITDA?
Vistagen Therapeutics, Inc. Common Stock's EBITDA is -$69.5M, based on as-reported figures from SEC (XBRL) filings.
What is Vistagen Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Vistagen Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -1.52, based on as-reported figures from SEC (XBRL) filings.
What is Vistagen Therapeutics, Inc. Common Stock's EBITDA Margin?
Vistagen Therapeutics, Inc. Common Stock's EBITDA Margin is -2777.2%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · VTGNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth+504.9%+3200.0%+29.5%+41.0%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue1004.3%3695.1%6550.8%7872.5%
Loss from operations
% of revenue-904.3%-3595.1%-6450.8%-7772.5%
Other income, net:
Interest income, net
Other income—
Loss before income taxes
Income taxes
Net loss
% of revenue-882.8%-3499.8%-6237.3%-7526.0%
Basic, net loss per common share (in dollars per share)
Diluted, net loss per common share (in dollars per share)